The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00195702?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
